Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19: A retrospective, cohort study

Diabetes Obes Metab. 2021 Aug;23(8):1995-2000. doi: 10.1111/dom.14393. Epub 2021 Apr 16.

Authors

Samah Hayek¹, Yatir Ben-Shlomo¹, Ran Balicer^{1

2}, Katherine Byrne³, Mark Katz¹, Eldad Kepten¹, Itamar Raz⁴, Eytan Roitman¹, Marcin Zychma³, Noam Barda^{1

5}

Affiliations

¹ Clalit Research Institute, Clalit Health Services, Ramat Gan, Israel.
² School of Public Health, Ben-Gurion University, Beer-Sheba, Israel.
³ Novo Nordisk International Operations, Zürich, Switzerland.
⁴ Diabetes Medical Center, Tel-Aviv, Israel.
⁵ Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Blood Glucose
COVID-19*
Cohort Studies
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Glycated Hemoglobin / analysis
Glycemic Control
Humans
Hypoglycemic Agents / therapeutic use
Retrospective Studies
SARS-CoV-2
Severity of Illness Index

Substances

Blood Glucose
Glycated Hemoglobin A
Hypoglycemic Agents